KARACHI: Hoechst Pakistan just handed shareholders one of the richest payouts on the exchange, and it's doing so while lining up a takeover of another pharmaceutical company.

The board approved an interim cash dividend of Rs80 per share, equivalent to 800 percent, during a meeting held Thursday, ruling out bonus shares, right shares or any other entitlement for the half-year.

Hoechst Pakistan Profit Surges 63%

Six-month unconsolidated profit to June 30 was up 63.4 percent at Rs2.196 billion, versus Rs1.344 billion last year. Sales barely budged just 2.4 percent higher, at Rs16.669 billion. It was further down the income statement where things picked up: gross profit climbed 17.2 percent to Rs6.588 billion, and operating profit did even better, jumping to Rs3.756 billion from about Rs2.404 billion, a rise of 56.7 percent. None of that came from stronger sales. It came from margins. Earnings per share, meanwhile, rose to Rs227.65 from Rs139.34.

Buried further down the same filing is what really matters here. Management has been given the green light to wrap up due diligence and nail down commercial terms binding offers, definitive agreements, the works for a possible acquisition. The target would be a pharmaceutical company, bought either directly or through a subsidiary.

Also Read: AGP Limited Approves Mega Pharma Merger to Enter Top 10

This isn't sudden. Back in March 2026, the board had already given in-principle approval to look at expansion options product partnerships, manufacturing investment, maybe a majority stake in another pharma firm. What changed on Thursday is that the exploratory phase is over. Management can now actually close due diligence and lock in terms, assuming regulators and the corporate side sign off.

800% Dividend Raises Questions

Pairing a sizeable new dividend with acquisition groundwork creates an interesting capital-allocation story. Hoechst is committing fresh cash to shareholders while simultaneously preparing for a potentially significant pharmaceutical transaction. The Rs80-per-share interim dividend represents a substantial payout, yet the company's operating cash generation suggests management sees room to pursue both shareholder returns and expansion. Unconsolidated cash and bank balances came in at Rs228.975 million at period-end, actually higher than the Rs134.916 million the company started the year with. Even after handing out a heavy dividend, Hoechst held onto enough cash flexibility to keep working out how it wants to fund and structure whatever acquisition comes next.

There's still a lot the filing doesn't say. No target has been named. No price tag. No date by which binding agreements need to be signed. The company has also not explained why it chose to distribute such a large payout at the same moment it's preparing for a capital-intensive transaction.

Pakistan's pharmaceutical sector has seen relatively few major consolidation moves in recent years, which makes Hoechst's dual announcement worth watching closely. A company generating enough cash to fund an 800 percent dividend and still pursue an acquisition simultaneously isn't showing financial strain it's showing confidence. Whether that confidence translates into a completed deal, and what it means for competition in Pakistan's pharma market, depends entirely on details Hoechst hasn't yet disclosed.